Pfizer pulls back from plan to expedite review of Covid shots in young kids; With Lander gone, here’s who could be Biden’s next science adviser

The FDA canceled a key meeting to discuss the submission, saying that the delay "will give the agency time to consider … additional data." ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        Pfizer and FDA pull back from plan to expedite review of Covid-19 vaccine in young children By Matthew Herper and Nicholas Florko and Helen Branswell FADEL SENNA/AFP via Getty Images The FDA canceled a key meeting planned for next week to discuss the submission, saying that the delay "will give the agency time to consider … additional data." Read More STAT+: Following Lander's resignation, here's who might be in line for White House science adviser By Lev Facher Evan Vucci/AP Among the rumored candidates to replace Eric Lander as White House science adviser, these five names stood out. Read More Authorization of new Covid-19 monoclonal expands arsenal of options against Omicron and its sister variant By Andrew Joseph The FDA authorized another Covid-19 monoclonal antibody treatment, expanding the supply of treatments that work against the Omicron variant. Read More Sponsor content by Genentech Charting a course for medicine’s future Download our latest e-book on the seismic shift that is taking place in science and medicine. Through a showcase of the interviews and panel discussions that took place on-stage at our 2021 STAT Summit — including with biotech visionaries like George Church, top executives at GlaxoSmithKline and Verily, and the minds behind the Biden administration's ARPA-H program — we underscore the important conversations that are taking place, as researchers, health care industry leaders, and policymakers navigate the future of science and medicine. STAT+: An FDA ruling on Cassava's Alzheimer's drug leaves bulls and bears waiting for more By Adam Feuerstein While the decision was a win for Cassava, a top official did not rule out further action against the company. Read More Fight over opioid prescribing — and when it turns criminal — heads to Supreme Court By Andrew Joseph Alex Hogan/STAT A ruling could enable aggressive prosecutions of prescribers' opioid prescribing, and lead to prescribers dropping pain patients from care. Read More Opinion: The White House's response to Lander's exit could determine whether science remains a factory for bullies By Sherry Moss and Morteza Mahmoudi Adobe Targets of bullying remain silent because they fear retaliation or losing their jobs, and don't trust their workplace will protect them. Read More Opinion: STAT+: Biopharma's response to the next pandemic depends on collaboration and the ability to learn and fail fast By Birgit Girshick Jon Cherry/Getty Images The accelerated development of Covid-19 vaccines and therapies can be chalked up to out-of-the-box collaboration and "fail fast" approaches. Read More Friday, February 11, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser